文献速递病毒性肝炎医院感染防控

血液恶性肿瘤及造血干细胞移植患者HBV再激活的筛查、监测、预防与治疗:系统综述

Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review.
PubMed 文献 · Clin Microbiol Infect · 2017-06-28

主要结果为:化疗前应筛查HBV;未接受预防的HBV阳性患者应每月监测HBV DNA;HBsAg阳性患者及HSCT患者应接受预防并给予第三代HBV药物;抗-HBc阳性淋巴瘤患者及HSCT患者应接受抗病毒预防。结论认为证据质量有待提高,但足以支持相关推荐。

要点

  • 血液恶性肿瘤患者化疗前应筛查HBV。
  • 未预防的HBV阳性患者应每月监测HBV DNA。
  • HBsAg阳性及HSCT患者应预防并选用第三代HBV药物。

核心结论

  • 证据质量有待提高,但现有证据水平足以支持本期杂志发表的推荐意见。

研究设计与样本

  • 采用Cochrane偏倚风险工具和Newcastle Ottawa质量评估量表进行偏倚风险评估。

主要发现

  • 血液恶性肿瘤患者应在化疗前进行HBV筛查。
  • 所有未接受预防的HBV阳性患者应每月监测HBV DNA水平。
  • HBsAg阳性血液恶性肿瘤患者及接受HSCT的患者应接受预防,并应提供第三代HBV药物。
  • 抗-HBc阳性淋巴瘤患者及接受HSCT的患者应接受抗病毒预防。

临床怎么用

  • 对血液恶性肿瘤患者化疗前筛查HBV,对未预防的HBV阳性者每月监测HBV DNA。
  • 对HBsAg阳性血液恶性肿瘤患者及HSCT患者给予预防并选用第三代HBV药物。
  • 对抗-HBc阳性淋巴瘤患者及HSCT患者给予抗病毒预防。

局限性

  • 需要更高质量的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The growth of new therapeutic options and practices increases the risk of hepatitis B virus (HBV) reactivation in patients with haematologic malignancies and/or patients undergoing haematologic stem cell transplantation (HSCT). OBJECTIVES: To provide a systematic review supporting recommendations for prevention, monitoring, prophylaxis and therapy of HBV reactivation in patients with haematologic malignancies and HSCT. DATA SOURCES: The systematic review was based on a strategy using PubMed and the Cochrane Library searching literature published from 1991 to December 31, 2016. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines were followed. SELECTION CRITERIA: Randomized control trials, prospective and retrospective cohort studies. RISK-OF-BIAS ASSESSMENT: Cochrane Risk of Bias Tool and Newcastle Ottawa Quality Assessment Scale. RESULTS: Forty-two studies of fair or good quality were included in this systematic review. The following main results were obtained: haematologic patients should be screened for HBV before chemotherapy; HBV DNA levels should be monthly monitored in all HBV-positive patients not receiving prophylaxis; hepatitis B surface antigen (HBsAg)-positive haematologic patients and patients undergoing HSCT should receive prophylaxis and third-generation HBV drugs should be provided; and anti-hepatitis B core protein-positive lymphoma patients and patients who underwent HSCT should receive antiviral prophylaxis. CONCLUSIONS: A higher quality of evidence is needed. However, the level of evidence was sufficient to support the recommendations published in this issue of the journal.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Gentile G, Andreoni M, Antonelli G, et al. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect. 2017. PMID: 28668465. doi:10.1016/j.cmi.2017.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。